Danaher Corporation
DHR
$165.99
-0.16%
Danaher Corporation is a global leader in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services, with a primary focus on manufacturing scientific instruments and consumables for the life sciences and diagnostic industries following its strategic divestiture of the Veralto segment. The company is distinguished by its renowned Danaher Business System, a continuous improvement philosophy that drives operational excellence, and its identity as a disciplined acquirer and integrator of businesses, building a portfolio of high-margin, recurring-revenue platforms. The current investor narrative is dominated by the stock's significant decline from its peak, debates over the valuation and strategic rationale of its recent acquisition of Masimo, and questions about the timing and strength of a recovery in its core life sciences and diagnostics end markets, which have faced post-pandemic normalization pressures.…
DHR
Danaher Corporation
$165.99
Related headlines
DHR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Danaher Corporation's 12-month outlook, with a consensus price target around $215.79 and implied upside of +30.0% versus the current price.
Average Target
$215.79
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$133 - $216
Analyst target range
Analyst coverage for Danaher appears limited in the provided dataset, with only 6 analysts cited for EPS estimates, and no explicit consensus price target, buy/hold/sell distribution, or target range is available in the key inputs. This suggests that while Danaher is a large-cap company, the specific consensus data is not provided, and the available institutional ratings show a pattern of reiterated bullishness; recent actions from firms like JP Morgan (Overweight), Jefferies (Buy), TD Cowen (Buy), and Guggenheim (Buy) in early 2026 indicate maintained positive sentiment despite the stock's decline. Without a defined target range, the signal strength is unclear, but the persistence of 'Buy' and 'Overweight' ratings from major firms in the face of a steep price drop suggests analysts see fundamental value at current levels, potentially viewing the Masimo acquisition and market softness as temporary headwinds; the wide dispersion in estimated EPS for the forward year, with a high of $12.09 and a low of $11.40, indicates relatively tight earnings expectations and lower uncertainty on the bottom-line trajectory.
Bulls vs Bears: DHR Investment Factors
The investment debate for Danaher centers on a clash between deteriorating near-term technicals and volatile fundamentals against a robust long-term financial foundation and a valuation that anticipates recovery. Currently, the bearish evidence from the severe price decline, earnings volatility, and weak momentum appears stronger, as the market is punishing the stock for its cyclical downturn and acquisition uncertainty. The single most important tension is the timing and magnitude of the earnings recovery priced into the forward P/E of 19.26x. If Danaher's core markets rebound and the Masimo integration succeeds, the current price could be a deep-value entry point. If the recovery is delayed or weaker than expected, the still-premium trailing multiples suggest further downside risk.
Bullish
- Strong Free Cash Flow & Balance Sheet: Danaher generates robust free cash flow of $5.26 billion TTM, providing ample internal funding for strategic moves like the Masimo acquisition. The balance sheet is conservative with a debt-to-equity ratio of 0.35 and a current ratio of 1.87, indicating low financial risk and significant liquidity.
- Attractive Forward Valuation: The stock's forward P/E of 19.26x is reasonable for a high-quality industrial/healthcare hybrid and represents a significant discount to its trailing P/E of 44.80x. This gap implies the market is pricing in a strong earnings recovery, with forward EPS estimates of $11.54.
- Analyst Sentiment Remains Bullish: Despite the stock's 36% decline from its peak, major firms like JP Morgan, Jefferies, and Guggenheim maintain 'Buy' or 'Overweight' ratings. This persistent positive sentiment suggests institutional confidence in the long-term thesis and views current weakness as a buying opportunity.
- High-Margin, Recurring Revenue Model: The company maintains strong profitability with a trailing gross margin of 60.9% and an operating margin of 20.9%. Its focus on life sciences and diagnostics post-Veralto divestiture creates a portfolio with high-margin, recurring revenue streams.
Bearish
- Severe Earnings & Revenue Volatility: Quarterly net income has swung dramatically, from $954M in Q1 2025 to $555M in Q2, to $908M in Q3, and $1.20B in Q4. This inconsistency, alongside modest 4.59% YoY revenue growth in Q4, signals underlying operational instability and market headwinds.
- Deep, Persistent Price Downtrend: The stock is in a pronounced downtrend, down 10.96% over the past year and 19.98% over the past three months. It trades at a mere 0.2% of its 52-week range ($174.6 to $242.8), indicating intense selling pressure and a lack of near-term catalysts for recovery.
- Elevated Trailing Valuation Multiples: A trailing P/E of 44.80x and EV/EBITDA of 25.30 are at premium levels, even if justified by margins. These multiples are vulnerable to compression if the anticipated earnings recovery falters or if growth stock multiples contract further in a higher-rate environment.
- Post-Pandemic Market Normalization Pressures: The core life sciences and diagnostics end markets are facing post-pandemic normalization, which pressures growth. The strategic rationale and valuation of the recent Masimo acquisition are also under investor scrutiny, adding uncertainty.
DHR Technical Analysis
The prevailing price trend for Danaher is a pronounced and sustained downtrend, with the stock down 10.96% over the past year and trading near the very bottom of its 52-week range. With a current price of $175.15, it sits just 0.3% above its 52-week low of $174.6, positioning it at a mere 0.2% of its 52-week range ($174.6 to $242.8), which signals extreme technical weakness and suggests the stock is in a capitulation or deep value zone, though it risks being a 'falling knife' without a clear catalyst. Recent momentum is severely negative and accelerating the longer-term downtrend, with the stock down 19.98% over the past three months and a further 8.20% over the past month; this deceleration in the rate of decline is a minor silver lining but the persistent negative momentum, underscored by a massive -40.00 point of relative strength underperformance versus the S&P 500 over the past year, indicates intense selling pressure and a lack of near-term bullish conviction. Key technical support is firmly established at the 52-week low of $174.6, with a breakdown below this level potentially triggering another leg down, while initial resistance lies far above at the 52-week high of $242.8; the stock's beta of 0.986 indicates its volatility is nearly in line with the broader market, but its deep drawdown of -27.64% highlights significant idiosyncratic risk that has not been hedged by a low beta, making position sizing critical.
Beta
0.84
0.84x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$163-$243
Price range past year
Annual Return
-15.6%
Cumulative gain past year
| Period | DHR Return | S&P 500 |
|---|---|---|
| 1m | -15.3% | +8.2% |
| 3m | -22.8% | +9.0% |
| 6m | -25.0% | +10.5% |
| 1y | -15.6% | +26.5% |
| ytd | -28.0% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DHR Fundamental Analysis
Danaher's revenue trajectory shows modest growth but significant volatility in profitability, with Q4 2025 revenue of $6.84 billion representing a 4.59% year-over-year increase; however, examining sequential quarters reveals instability, as revenue grew from $5.74 billion in Q1 to $6.84 billion in Q4, but net income swung dramatically from $954 million to $555 million to $908 million to $1.20 billion, indicating underlying operational or non-recurring item volatility. The company is profitable with a strong gross margin profile, as evidenced by a Q4 gross margin of 58.0% and a trailing net margin of 14.71%, but quarterly net income has been inconsistent, and the operating margin of 20.91% suggests healthy core profitability that is being impacted by other expenses; the gross margin has shown resilience, fluctuating between 58.0% and 66.6% over the last four reported quarters. The balance sheet is robust with a strong current ratio of 1.87 and a manageable debt-to-equity ratio of 0.35, indicating ample liquidity and a conservative capital structure; the company generates substantial cash flow, with trailing twelve-month free cash flow of $5.26 billion, providing significant internal funding capacity for dividends, share repurchases, and strategic acquisitions like Masimo, while a Return on Equity of 6.88% reflects pressured returns in the current environment.
Quarterly Revenue
$6.8B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.57%
Latest Quarter
Free Cash Flow
$5.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DHR Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. Danaher's trailing PE ratio is elevated at 44.80x, while its forward PE is significantly lower at 19.26x; this substantial gap implies the market is pricing in a strong recovery in earnings, with forward estimates of $11.54 per share representing a major inflection from recent quarterly results. Compared to sector averages, Danaher's trailing PE of 44.80x is difficult to contextualize without a specific industry average, but its forward PE of 19.26x appears more reasonable for a high-quality industrial/healthcare hybrid; the stock's Price-to-Sales ratio of 6.59 and EV/EBITDA of 25.30 further indicate the market is applying a premium multiple, likely justified by its strong margins, recurring revenue model, and acquisition-driven growth strategy. Historically, Danaher's current trailing PE of 44.80x sits well above its own historical range observed in recent quarters, which has typically fluctuated between the high 20s and mid-60s; however, this elevated multiple is partly a function of depressed earnings in the denominator, and the stock's valuation on a forward basis is more aligned with historical norms, suggesting the market is looking through near-term weakness toward a normalized earnings profile.
PE
44.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~64x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks stem from significant quarterly earnings volatility, where net income swung from $954M to $555M between Q1 and Q2 2025, indicating sensitivity to non-recurring items or operational inefficiencies. While free cash flow is strong at $5.26B, the company's valuation depends on a sharp earnings rebound to justify its forward P/E; a failure to meet the $11.54 EPS estimate would trigger multiple compression. Furthermore, the strategic pivot and the Masimo acquisition introduce integration and execution risks that could pressure margins from their current 20.9% operating level.
Market & Competitive Risks are elevated due to Danaher's premium valuation trading at a forward P/E of 19.26x and a P/S of 6.59, which leaves it exposed to sector-wide de-rating if interest rates remain elevated. The stock's beta of 0.986 suggests market-correlated moves, but its -27.64% max drawdown highlights severe idiosyncratic risk from its specific end-market exposure to the softening life sciences sector. Competitive and regulatory pressures in diagnostics, combined with investor skepticism over the Masimo deal's value, as noted in recent news, create persistent overhangs that could delay a re-rating.
Worst-Case Scenario involves a prolonged downturn in life sciences capital expenditure, coupled with a botched Masimo integration and a broader market sell-off compressing growth stock multiples. In this adverse scenario, the stock could breach its 52-week low of $174.6 and re-test levels implied by a more distressed valuation, such as a forward P/E of 15x on lowered earnings, suggesting a downside target near $165. This would represent a loss of approximately -6% from the current price, with the potential for a steeper decline to the -27.64% drawdown level if sentiment completely sours, implying a risk to the $140 range.